Ghaith Noaiseh, MD

Professional Background

Training:

Fellowship Rheumatology
07/2010 – 06/2012 University of Pennsylvania, Philadelphia, Pennsylvania

Residency and Chief residency Internal Medicine
07/2005 – 06/2007 Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, Ohio

Internship Internal Medicine
06/2004 – 06/2005 Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, Ohio

Internship Laboratory Medicine
10/2002 – 07/2003 Tishreen University Hospital, Lattakia, Syria

Research Focus:

1. Clinical trials in Sjogren’s Syndrome and Systemic Lupus erythematosus.
2. Epidemiology, clinical spectrum and management of Neurological and Vasculitic manifestations of Sjogren’s Syndrome.

Clinical Interests:

Management of complex Sjogren’s Syndrome patients
Systemic lupus erythematosus

Following the completing of Internal Medicine Residency, Dr. Noaiseh joined the Cleveland Clinic as an academic hospitalist from 2007-2010.
In 2012, he joined the faculty at the University of Pittsburgh where he worked at UPMC Lupus Center of Excellence and established UPMC Sjogren’s Clinic in 2014.
He conducted many NIH and Pharma-sponsored clinical trials in the fields of Sjogren’s Syndrome and SLE and was part of the Lupus Clinical Investigators Network (LuCIN); a North American-based lupus clinical trials network of 57 of the largest academic research medical centers in US and Canada.

Currently, Dr. Noaiseh directs the KU Sjogren's clinic in collaboration with a multidisciplinary team of experts in otolaryngology, ophthalmology, neurology, pulmonary and pathology specialists at KU.

He serves as the clinical lead for Sjogren’s Foundations’(SSF) Clinical Practice Guidelines committee aiming at developing guidelines for management of Vasculitis in Sjogren’s Disease, he is also a panel member for the SSF central and peripheral nervous system Clinical Practice Guidelines committees.

• MD, Medicine , Tishreen University Faculty of Medicine , Lattakia, Syria
• Internship, Laboratory Medicine, Tishreen University Hospital , Lattakia, Syria
• Internship, Medicine , Case Western Reserve University/St. Vincent Charity Hospital, Cleveland, OH
• Residency, Internal Medicine, Case Western Reserve University/St. Vincent Charity Hospital, Cleveland , OH
• Clinical Fellowship, Rheumatology , University of Pennsylvania, Philadelphia, PA

• KUMC- Division of Rheumatology , Member, 2020 - Present

---

Research

Overview

Selected publications:
1. Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach.
Noaiseh G, Baer AN. Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101475. doi: 10.1016/j.berh.2019.101475. Epub 2020 Jan 28.PMID: 32005417

2. Unique Sjögren's syndrome patient subsets defined by molecular features.
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW.
Rheumatology (Oxford). 2020 Apr 1;59(4):860-868. doi: 10.1093/rheumatology/kez335.PMID: 31497844

3. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, Utset TO, Genovese MC, Wallace DJ, McNamara J, Boyle K, Keyes-Elstein L, Browning JL, Franchimont N, Smith K, Guthridge JM, Sanz I, James JA; Autoimmunity Centers of Excellence.
Arthritis Rheumatol. 2018 Sep;70(9):1470-1480. doi: 10.1002/art.40513. Epub 2018 Jul 18.PMID: 29604186

4. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
Noaiseh G, Baker JF, Vivino FB.
Clin Exp Rheumatol. 2014 Jul-Aug;32(4):575-7. Epub 2014 Jul 23.PMID: 25065774